Success Metrics

Clinical Success Rate
100.0%

Based on 2 completed trials

Completion Rate
100%(2/2)
Active Trials
0(0%)
Results Posted
100%(2 trials)

Phase Distribution

Ph phase_1
1
50%
Ph phase_2
1
50%

Phase Distribution

1

Early Stage

1

Mid Stage

0

Late Stage

Phase Distribution2 total trials
Phase 1Safety & dosage
1(50.0%)
Phase 2Efficacy & side effects
1(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

2 of 2 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

2

all time

Status Distribution
Completed(2)

Detailed Status

Completed2

Development Timeline

Analytics

Development Status

Total Trials
2
Active
0
Success Rate
100.0%
Most Advanced
Phase 2

Trials by Phase

Phase 11 (50.0%)
Phase 21 (50.0%)

Trials by Status

completed2100%

Recent Activity

0 active trials
Showing 2 of 2
completedphase_2

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

NCT01644617
completedphase_1

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

NCT01678807

Clinical Trials (2)

Showing 2 of 2 trials
NCT01644617Phase 2

A Dose-Ranging Study of the Safety and Effectiveness of MK-8237 in the Treatment of House Dust Mite (HDM) Induced Allergic Rhinitis/Rhinoconjunctivitis in Adults (MK-8237-003/P07627)

Completed
NCT01678807Phase 1

Safety Study of MK-8237 Treatment in House-Dust-Mite Allergic Adolescents (MK-8237-008)

Completed

All 2 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
2